FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:618-629 February 13, 2003 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Supplementary Material Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

The selective estrogen-receptor modulators (SERMs) represent a major therapeutic advance for clinical practice. Unlike estrogens, which are uniformly agonists, and antiestrogens, which are uniformly antagonists, the SERMs exert selective agonist or antagonist effects on various estrogen target tissues. The SERMs are chemically diverse compounds that lack the steroid structure of estrogens (Figure 1) but possess a tertiary structure that allows them to bind to the estrogen receptor. Although some members of this class of drugs have been available for decades, their tissue-specificity in humans has only recently been recognized. Certain phytoestrogens, such as genistein, also appear to have . . . [Full Text of this Article]

Mechanisms of Action

Action on Target Tissues

Bone

Breast

Genitourinary Tract

Cardiovascular System

Central Nervous System

Therapeutic Uses

General

Prevention and Treatment of Osteoporosis

Treatment and Prevention of Breast Cancer

Future Directions

Source Information

From the Division of Endocrinology and Metabolism, Department of Internal Medicine (B.L.R.), and the Department of Oncology (L.C.H.), Mayo Clinic and Mayo Foundation, Rochester, Minn.

Address reprint requests to Dr. Riggs at the Mayo Clinic, 200 First St. SW, N. 6 Plummer, Rochester, MN 55905.

Related Letters:

Selective Estrogen-Receptor Modulators
Barham M., Riggs B. L., Hartmann L. C.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:2259, May 29, 2003. Correspondence

This article has been cited by other articles:

• Modder, U. I., Monroe, D. G., Fraser, D. G., Spelsberg, T. C., Rosen, C. J., Gehin, M., Chambon, P., O'Malley, B. W., Khosla, S. (2009). Skeletal Consequences of Deletion of Steroid Receptor Coactivator-2/Transcription Intermediary Factor-2. J. Biol. Chem. 284: 18767-18777 [Abstract] [Full Text]  
• Chandrasekaran, A., McKeand, W. E., Sullivan, P., DeMaio, W., Stoltz, R., Scatina, J. (2009). Metabolic Disposition of [14C]Bazedoxifene in Healthy Postmenopausal Women. Drug Metab. Dispos. 37: 1219-1225 [Abstract] [Full Text]  
• Khan, A., Grey, A., Shoback, D. (2009). Medical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. J. Clin. Endocrinol. Metab. 94: 373-381 [Abstract] [Full Text]  
• Kupfer, R., Swanson, L., Chow, S., Staub, R. E., Zhang, Y. L., Cohen, I., Christians, U. (2008). Oxidative in Vitro Metabolism of Liquiritigenin, a Bioactive Compound Isolated from the Chinese Herbal Selective Estrogen {beta}-Receptor Agonist MF101. Drug Metab. Dispos. 36: 2261-2269 [Abstract] [Full Text]  
• Jacobson, B. C., Moy, B., Colditz, G. A., Fuchs, C. S. (2008). Postmenopausal Hormone Use and Symptoms of Gastroesophageal Reflux. Arch Intern Med 168: 1798-1804 [Abstract] [Full Text]  
• Chen, Y.-J., Lee, M.-T., Yao, H.-C., Hsiao, P.-W., Ke, F.-C., Hwang, J.-J. (2008). Crucial Role of Estrogen Receptor-{alpha} Interaction with Transcription Coregulators in Follicle-Stimulating Hormone and Transforming Growth Factor {beta}1 Up-Regulation of Steroidogenesis in Rat Ovarian Granulosa Cells. Endocrinology 149: 4658-4668 [Abstract] [Full Text]  
• Razmara, A., Sunday, L., Stirone, C., Wang, X. B., Krause, D. N., Duckles, S. P., Procaccio, V. (2008). Mitochondrial Effects of Estrogen Are Mediated by Estrogen Receptor {alpha} in Brain Endothelial Cells. J. Pharmacol. Exp. Ther. 325: 782-790 [Abstract] [Full Text]  
• Mankoff, D. A., Link, J. M., Linden, H. M., Sundararajan, L., Krohn, K. A. (2008). Tumor Receptor Imaging. JNM 49: 149S-163S [Abstract] [Full Text]  
• Abukhdeir, A. M., Vitolo, M. I., Argani, P., De Marzo, A. M., Karakas, B., Konishi, H., Gustin, J. P., Lauring, J., Garay, J. P., Pendleton, C., Konishi, Y., Blair, B. G., Brenner, K., Garrett-Mayer, E., Carraway, H., Bachman, K. E., Park, B. H. (2008). Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc. Natl. Acad. Sci. USA 105: 288-293 [Abstract] [Full Text]  
• Kawagoe, J., Ohmichi, M., Tsutsumi, S., Ohta, T., Takahashi, K., Kurachi, H. (2007). Mechanism of the Divergent Effects of Estrogen on the Cell Proliferation of Human Umbilical Endothelial Versus Aortic Smooth Muscle Cells. Endocrinology 148: 6092-6099 [Abstract] [Full Text]  
• Duffy, C., Perez, K., Partridge, A. (2007). Implications of Phytoestrogen Intake for Breast Cancer. CA Cancer J Clin 57: 260-277 [Abstract] [Full Text]  
• Su, Y., Simmen, F. A., Xiao, R., Simmen, R. C. M. (2007). Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiol. Genomics 30: 8-16 [Abstract] [Full Text]  
• Moritz, A., Gust, R., Pertz, H. H. (2007). Characterization of the Relaxant Response to N,N'-Dipropyl-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine in Porcine Coronary Arteries. J. Pharmacol. Exp. Ther. 321: 699-706 [Abstract] [Full Text]  
• Leung, K.-C., Brce, J., Doyle, N., Lee, H. J., Leong, G. M., Sjogren, K., Ho, K. K. Y. (2007). Regulation of Growth Hormone Signaling by Selective Estrogen Receptor Modulators Occurs through Suppression of Protein Tyrosine Phosphatases. Endocrinology 148: 2417-2423 [Abstract] [Full Text]  
• Liu, J., Matsuo, H., Xu, Q., Chen, W., Wang, J., Maruo, T. (2007). Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro. Hum Reprod 22: 1253-1259 [Abstract] [Full Text]  
• Bolego, C., Vegeto, E., Pinna, C., Maggi, A., Cignarella, A. (2006). Selective Agonists of Estrogen Receptor Isoforms: New Perspectives for Cardiovascular Disease. Arterioscler. Thromb. Vasc. Bio. 26: 2192-2199 [Abstract] [Full Text]  
• Doshida, M., Ohmichi, M., Tsutsumi, S., Kawagoe, J., Takahashi, T., Du, B., Mori-Abe, A., Ohta, T., Saitoh-Sekiguchi, M., Takahashi, K., Kurachi, H. (2006). Raloxifene Increases Proliferation and Up-regulates Telomerase Activity in Human Umbilical Vein Endothelial Cells. J. Biol. Chem. 281: 24270-24278 [Abstract] [Full Text]  
• Frasor, J., Chang, E. C., Komm, B., Lin, C.-Y., Vega, V. B., Liu, E. T., Miller, L. D., Smeds, J., Bergh, J., Katzenellenbogen, B. S. (2006). Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.. Cancer Res. 66: 7334-7340 [Abstract] [Full Text]  
• Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., Hart, R. G., Howard, G., Kelly-Hayes, M., Nixon, J.V., Sacco, R. L. (2006). Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.. Circulation 113: e873-e923 [Abstract] [Full Text]  
• Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., Hart, R. G., Howard, G., Kelly-Hayes, M., Nixon, J.V., Sacco, R. L. (2006). Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.. Stroke 37: 1583-1633 [Abstract] [Full Text]  
• Crosignani, P., Olive, D., Bergqvist, A., Luciano, A. (2006). Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update 12: 179-189 [Abstract] [Full Text]  
• Moller, R. A, Fisher, J. M, Taylor, A. E, Kolluri, S., Gardner, M. J, Obach, R S., Walsky, R. L (2006). Effects of Steady-State Lasofoxifene on CYP2D6- and CYP2E1-Mediated Metabolism. The Annals of Pharmacotherapy 40: 32-37 [Abstract] [Full Text]  
• Helvering, L. M., Liu, R., Kulkarni, N. H., Wei, T., Chen, P., Huang, S., Lawrence, F., Halladay, D. L., Miles, R. R., Ambrose, E. M., Sato, M., Ma, Y. L., Frolik, C. A., Dow, E. R., Bryant, H. U., Onyia, J. E. (2005). Expression Profiling of Rat Femur Revealed Suppression of Bone Formation Genes by Treatment with Alendronate and Estrogen but Not Raloxifene. Mol. Pharmacol. 68: 1225-1238 [Abstract] [Full Text]  
• Rudmann, D. G., Cohen, I. R., Robbins, M. R., Coutant, D. E., Henck, J. W. (2005). Androgen Dependent Mammary Gland Virilism in Rats Given the Selective Estrogen Receptor Modulator LY2066948 Hydrochloride. Toxicol Pathol 33: 711-719 [Abstract] [Full Text]  
• Zhang, X., Shu, X.-O., Li, H., Yang, G., Li, Q., Gao, Y.-T., Zheng, W. (2005). Prospective Cohort Study of Soy Food Consumption and Risk of Bone Fracture Among Postmenopausal Women. Arch Intern Med 165: 1890-1895 [Abstract] [Full Text]  
• Kondo, H., Nifuji, A., Takeda, S., Ezura, Y., Rittling, S. R., Denhardt, D. T., Nakashima, K., Karsenty, G., Noda, M. (2005). Unloading Induces Osteoblastic Cell Suppression and Osteoclastic Cell Activation to Lead to Bone Loss via Sympathetic Nervous System. J. Biol. Chem. 280: 30192-30200 [Abstract] [Full Text]  
• Rosen, C. J. (2005). Postmenopausal Osteoporosis. NEJM 353: 595-603 [Full Text]  
• Esposito, E., Iacono, A., Raso, G. M., Pacilio, M., Coppola, A., Di Carlo, R., Meli, R. (2005). Raloxifene, a Selective Estrogen Receptor Modulator, Reduces Carrageenan-Induced Acute Inflammation in Normal and Ovariectomized Rats. Endocrinology 146: 3301-3308 [Abstract] [Full Text]  
• Peeva, E., Venkatesh, J., Diamond, B. (2005). Tamoxifen Blocks Estrogen-Induced B Cell Maturation but Not Survival. J. Immunol. 175: 1415-1423 [Abstract] [Full Text]  
• Gibney, J., Johannsson, G., Leung, K.-C., Ho, K. K. Y. (2005). Comparison of the Metabolic Effects of Raloxifene and Oral Estrogen in Postmenopausal and Growth Hormone-Deficient Women. J. Clin. Endocrinol. Metab. 90: 3897-3903 [Abstract] [Full Text]  
• Leung, F. P., Yao, X., Lau, C.-W., Ko, W.-H., Lu, L., Huang, Y. (2005). Raloxifene relaxes rat intrarenal arteries by inhibiting Ca2+ influx. Am. J. Physiol. Renal Physiol. 289: F137-F144 [Abstract] [Full Text]  
• Chen, J., Kim, J., Dalton, J. T. (2005). Discovery and Therapeutic Promise of Selective Androgen Receptor Modulators. Mol. Interv. 5: 173-188 [Abstract] [Full Text]  
• Tirri, M. E., Huttunen, R. J., Toivonen, J., Harkonen, P. L., Soini, J. T., Hanninen, P. E. (2005). Two-Photon Excitation in Fluorescence Polarization Receptor-Ligand Binding Assay. J Biomol Screen 10: 314-319 [Abstract]  
• Elloso, M M., Phiel, K., Henderson, R. A, Harris, H. A, Adelman, S. J (2005). Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands. J Endocrinol 185: 243-252 [Abstract] [Full Text]  
• Cheong, J L, Bucknall, R (2005). Retinal vein thrombosis associated with a herbal phytoestrogen preparation in a susceptible patient. Postgrad. Med. J. 81: 266-267 [Abstract] [Full Text]  
• Chadwick, C. C., Chippari, S., Matelan, E., Borges-Marcucci, L., Eckert, A. M., Keith, J. C. Jr., Albert, L. M., Leathurby, Y., Harris, H. A., Bhat, R. A., Ashwell, M., Trybulski, E., Winneker, R. C., Adelman, S. J., Steffan, R. J., Harnish, D. C. (2005). Identification of pathway-selective estrogen receptor ligands that inhibit NF-{kappa}B transcriptional activity. Proc. Natl. Acad. Sci. USA 102: 2543-2548 [Abstract] [Full Text]  
• Liu, B., Edgerton, S., Yang, X., Kim, A., Ordonez-Ercan, D., Mason, T., Alvarez, K., McKimmey, C., Liu, N., Thor, A. (2005). Low-Dose Dietary Phytoestrogen Abrogates Tamoxifen-Associated Mammary Tumor Prevention. Cancer Res. 65: 879-886 [Abstract] [Full Text]  
• Brass, L. M. (2004). Hormone Replacement Therapy and Stroke: Clinical Trials Review. Stroke 35: 2644-2647 [Abstract] [Full Text]  
• Yki-Jarvinen, H. (2004). Thiazolidinediones. NEJM 351: 1106-1118 [Full Text]  
• Angelopoulos, N, Barbounis, V, Livadas, S, Kaltsas, D, Tolis, G (2004). Effects of estrogen deprivation due to breast cancer treatment. Endocr Relat Cancer 11: 523-535 [Abstract] [Full Text]  
• Stafford, R. S., Drieling, R. L., Hersh, A. L. (2004). National Trends in Osteoporosis Visits and Osteoporosis Treatment, 1988-2003. Arch Intern Med 164: 1525-1530 [Abstract] [Full Text]  
• Chen, H., Hewison, M., Hu, B., Sharma, M., Sun, Z., Adams, J. S. (2004). An Hsp27-related, Dominant-negative-acting Intracellular Estradiol-binding Protein. J. Biol. Chem. 279: 29944-29951 [Abstract] [Full Text]  
• Tsang, S.-Y., Yao, X., Essin, K., Wong, C.-M., Chan, F. L., Gollasch, M., Huang, Y. (2004). Raloxifene Relaxes Rat Cerebral Arteries In Vitro and Inhibits L-Type Voltage-Sensitive Ca2+ Channels. Stroke 35: 1709-1714 [Abstract] [Full Text]  
• Ratliff, B., Dietze, E. C., Bean, G. R., Moore, C., Wanko, S., Seewaldt, V. L. (2004). Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine. JNCI J Natl Cancer Inst 96: 883-883 [Full Text]  
• Li, D., Das, S., Yamada, T., Samuels, H. H. (2004). The NRIF3 Family of Transcriptional Coregulators Induces Rapid and Profound Apoptosis in Breast Cancer Cells. Mol. Cell. Biol. 24: 3838-3848 [Abstract] [Full Text]  
• Ke, H. Z., Foley, G. L., Simmons, H. A., Shen, V., Thompson, D. D. (2004). Long-Term Treatment of Lasofoxifene Preserves Bone Mass and Bone Strength and Does Not Adversely Affect the Uterus in Ovariectomized Rats. Endocrinology 145: 1996-2005 [Abstract] [Full Text]  
• Krieg, A. J., Krieg, S. A., Ahn, B. S., Shapiro, D. J. (2004). Interplay between Estrogen Response Element Sequence and Ligands Controls in Vivo Binding of Estrogen Receptor to Regulated Genes. J. Biol. Chem. 279: 5025-5034 [Abstract] [Full Text]  
• Naciff, J. M., Daston, G. P. (2004). Toxicogenomic Approach to Endocrine Disrupters: Identification of a Transcript Profile Characteristic of Chemicals with Estrogenic Activity. Toxicol Pathol 32: 59-70 [Abstract]  
• Brown, S. A., Sharpless, J. L. (2004). Osteoporosis: An Under-appreciated Complication of Diabetes. Clin. Diabetes 22: 10-20 [Abstract] [Full Text]  
• Moverare, S., Dahllund, J., Andersson, N., Islander, U., Carlsten, H., Gustafsson, J.-A., Nilsson, S., Ohlsson, C. (2003). Estren Is a Selective Estrogen Receptor Modulator with Transcriptional Activity. Mol. Pharmacol. 64: 1428-1433 [Abstract] [Full Text]  
• Kawagoe, J., Ohmichi, M., Takahashi, T., Ohshima, C., Mabuchi, S., Takahashi, K., Igarashi, H., Mori-Abe, A., Saitoh, M., Du, B., Ohta, T., Kimura, A., Kyo, S., Inoue, M., Kurachi, H. (2003). Raloxifene Inhibits Estrogen-induced Up-regulation of Telomerase Activity in a Human Breast Cancer Cell Line. J. Biol. Chem. 278: 43363-43372 [Abstract] [Full Text]  
• Bross, P. F., Baird, A., Chen, G., Jee, J. M., Lostritto, R. T., Morse, D. E., Rosario, L. A., Williams, G. M., Yang, P., Rahman, A., Williams, G., Pazdur, R. (2003). Fulvestrant in Postmenopausal Women with Advanced Breast Cancer. Clin. Cancer Res. 9: 4309-4317 [Abstract] [Full Text]  
• Barham, M., Riggs, B. L., Hartmann, L. C. (2003). Selective Estrogen-Receptor Modulators. NEJM 348: 2259-2259 [Full Text]